愛柯迪(600933.SH):擬出資3000萬元參與設立產業基金
格隆匯11月29日丨愛柯迪(600933.SH)公佈,為落實企業戰略發展規劃,在穩固發展公司主業的同時,實現可持續發展,公司作為有限合夥人與基金管理人暨普通合夥人寧波藍湖投資管理有限公司及其他有限合夥人於2021年11月26日簽署了《寧波江北創業投資合夥企業(有限合夥)合夥協議》,共同發起設立寧波江北創業投資合夥企業(有限合夥)。本合夥企業目標總規模4.72億元人民幣,公司作為有限合夥人以自有資金出資3000萬元,出資比例為6.36%。該合夥企業將根據合夥協議約定從事投資業務,通過合法經營實現資本增值,為投資人創造價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.